bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies profit margin
Profit margin (net margin) is net income as a percentage of revenue.
bioAffinity Technologies's profit margin for the twelve months ending Jun 30, 2026 was -257.3%. For fiscal 2025 it was -242.0%, against -96.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -242.0% | −145.4 |
| FY2024 | Dec 31, 2024 | -96.6% | +216.8 |
| FY2023 | Dec 31, 2023 | -313.4% | −195.2 |
| FY2022 | Dec 31, 2022 | -118.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -222.8% | +97.0 |
| Q1 FY2026 | Mar 31, 2026 | -268.6% | −125.1 |
| Q4 FY2025 | Dec 31, 2025 | -197.0% | −62.6 |
| Q3 FY2025 | Sep 30, 2025 | -349.3% | −264.2 |
| Q2 FY2025 | Jun 30, 2025 | -319.9% | −231.9 |
| Q1 FY2025 | Mar 31, 2025 | -143.5% | −62.0 |
| Q4 FY2024 | Dec 31, 2024 | -134.4% | −29.4 |
| Q3 FY2024 | Sep 30, 2024 | -85.1% | +682.4 |
| Q2 FY2024 | Jun 30, 2024 | -88.0% | +8728.3 |
| Q1 FY2024 | Mar 31, 2024 | -81.5% | +3.3 |
| Q4 FY2023 | Dec 31, 2023 | -105.0% | −80.7 |
| Q3 FY2023 | Sep 30, 2023 | -767.5% | +427011.5 |
| Q2 FY2023 | Jun 30, 2023 | -8816.4% | −2074.2 |
| Q1 FY2023 | Mar 31, 2023 | -84.9% | – |
| Q4 FY2022 | Dec 31, 2022 | -24.3% | – |
| Q3 FY2022 | Sep 30, 2022 | -427779.0% | – |
| Q2 FY2022 | Jun 30, 2022 | -6742.1% | – |